BeOne Medicines (ONC) Long-Term Deferred Tax (2016 - 2023)
Historic Long-Term Deferred Tax for BeOne Medicines (ONC) over the last 8 years, with Q4 2023 value amounting to $2.0 billion.
- BeOne Medicines' Long-Term Deferred Tax fell 238.3% to $2.0 billion in Q4 2023 from the same period last year, while for Dec 2023 it was $2.0 billion, marking a year-over-year decrease of 238.3%. This contributed to the annual value of $2.0 billion for FY2023, which is 238.3% down from last year.
- Per BeOne Medicines' latest filing, its Long-Term Deferred Tax stood at $2.0 billion for Q4 2023, which was down 238.3% from $2.1 billion recorded in Q4 2022.
- In the past 5 years, BeOne Medicines' Long-Term Deferred Tax ranged from a high of $2.1 billion in Q4 2022 and a low of $30.5 million during Q1 2019
- Over the past 5 years, BeOne Medicines' median Long-Term Deferred Tax value was $66.0 million (recorded in 2020), while the average stood at $328.5 million.
- As far as peak fluctuations go, BeOne Medicines' Long-Term Deferred Tax surged by 15583.34% in 2019, and later crashed by 238.3% in 2023.
- BeOne Medicines' Long-Term Deferred Tax (Quarter) stood at $37.9 million in 2019, then surged by 74.07% to $66.0 million in 2020, then surged by 61.98% to $106.8 million in 2021, then soared by 1846.59% to $2.1 billion in 2022, then dropped by 2.38% to $2.0 billion in 2023.
- Its Long-Term Deferred Tax stands at $2.0 billion for Q4 2023, versus $2.1 billion for Q4 2022 and $103.4 million for Q2 2022.